Searched for
BIOLOGICS FACILITY BENGALURU
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilarsOneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSourc...- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Karnataka launches India’s first state-led spacetech CoE in BengaluruKarnataka has launched India's first state-led Centre of Excellence for Space Technology (CoE SpaceTech Foundation) in Bengaluru. This init...
- Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classificationBiocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classific...
- Biocon shares surge 5% after USFDA classifies Bengaluru site as VAIBiocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...
- Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDABiocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspecti...
- Biocon shares drop 2% after USFDA issues 4 observations for Bengaluru API facilityBiocon shares fell 2% to Rs 361.5 after the USFDA issued four observations following an inspection of its Bengaluru API facility. The compa...
- Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plantBiocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...
- US life sciences firm Cytiva opens new manufacturing site in PuneUS-based sciences company Cytiva has opened a new manufacturing facility and Experience Centre in Pune, India. The facility will double Cyt...
- Strides sells arm's manufacturing unit to Syngene International for Rs 702 croreStrides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene ...
- USFDA issues CRL for proposed biosimilar Insulin-R: BioconThe CRL cites additional data required in the BLA submission and an expectation of satisfactory implementation of a corrective and preventi...
- Biocon Biologics receives observations from USFDA: BioconThe USFDA conducted three on-site inspections of Biocon Biologics' seven manufacturing facilities spanning two sites in Bengaluru, India an...
- Biocon Biologics gets EU GMP certification from Ireland's HPRAThe company's new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru has received the certif...
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...
- Biocon gets EIR from USFDA for Bengaluru biologics unitBiopharma major Biocon reportedly received an Establishment Inspection Report (EIR) from US-FDA for its biologics drug product unit at Beng...
- Biocon subsidiary acquires research facility from Pfizer HealthcareBiocon shares were trading 0.64 per cent higher that their previous close at Rs 226.85 on the BSE.
- USFDA issues response letter for new drug application for insulin glargine: BioconBiocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.
- Zumutor Biologics partners with Catalent; complete study that may help cancer treatmentZumutor is in pre-phase one stage of developing a new version of a bestselling breast cancer drug with 20-fold functionality enhancement.
- Karnataka aims at being bio-economic power house of world: SiddaramaiahAbout 26% of the Biotech revenues of the country, particularly in terms of exports, are generated by the Biotech Industry in Karnataka, he ...
Load More
